Latest news with #ACAD
Yahoo
5 days ago
- Business
- Yahoo
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025
Company to host conference call and webcast on Wednesday, August 6, 2025, at 4:30 p.m. Eastern Time SAN DIEGO, July 23, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on August 6, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadia's website, under the investors section and will be archived there until November 5, 2025. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neurological and rare diseases to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. View source version on Contacts Investor Contact: Acadia Pharmaceuticals Kildani(858) 261-2872ir@ Acadia Pharmaceuticals Tieszen(858) 261-2950ir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-06-2025
- Business
- Yahoo
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
Launched on 06/19/2006, the First Trust NYSE Arca Biotechnology ETF (FBT) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market. For a long time now, the ETF industry has been flooded with products based on market capitalization weighted indexes, which are designed to represent the broader market or a particular market segment. Market cap weighted indexes offer a low-cost, convenient, and transparent way of replicating market returns, and are a good option for investors who believe in market efficiency. But, there are some investors who would rather invest in smart beta funds; these funds track non-cap weighted strategies, and are a strong option for those who prefer choosing great stocks in order to beat the market. By attempting to pick stocks that have a better chance of risk-return performance, non-cap weighted indexes are based on certain fundamental characteristics, or a combination of such. Even though this space provides many choices to investors--think one of the simplest methodologies like equal-weighting and more complicated ones like fundamental and volatility/momentum based weighting--not all have been able to deliver first-rate results. The fund is managed by First Trust Advisors. FBT has been able to amass assets over $994.75 million, making it one of the larger ETFs in the Health Care ETFs. This particular fund seeks to match the performance of the NYSE Arca Biotechnology Index before fees and expenses. The NYSE Arca Biotechnology Index is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. Since cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF's expense ratio. Operating expenses on an annual basis are 0.56% for this ETF, which makes it on par with most peer products in the space. The fund has a 12-month trailing dividend yield of 0.74%. ETFs offer diversified exposure and thus minimize single stock risk, but it is still important to delve into a fund's holdings before investing. Most ETFs are very transparent products and many disclose their holdings on a daily basis. FBT's heaviest allocation is in the Healthcare sector, which is about 100% of the portfolio. Looking at individual holdings, Acadia Pharmaceuticals Inc. (ACAD) accounts for about 4.7% of total assets, followed by Neurocrine Biosciences, Inc. (NBIX) and Alnylam Pharmaceuticals, Inc. (ALNY). FBT's top 10 holdings account for about 38.34% of its total assets under management. The ETF has lost about -4.37% and is up roughly 4.91% so far this year and in the past one year (as of 06/24/2025), respectively. FBT has traded between $145.67 and $182.19 during this last 52-week period. FBT has a beta of 0.60 and standard deviation of 20.49% for the trailing three-year period, which makes the fund a high risk choice in the space. With about 31 holdings, it has more concentrated exposure than peers . First Trust NYSE Arca Biotechnology ETF is a reasonable option for investors seeking to outperform the Health Care ETFs segment of the market. However, there are other ETFs in the space which investors could consider. SPDR S&P Biotech ETF (XBI) tracks S&P Biotechnology Select Industry Index and the iShares Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index. SPDR S&P Biotech ETF has $4.66 billion in assets, iShares Biotechnology ETF has $5.25 billion. XBI has an expense ratio of 0.35% and IBB changes 0.45%. Investors looking for cheaper and lower-risk options should consider traditional market cap weighted ETFs that aim to match the returns of the Health Care ETFs To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report First Trust NYSE Arca Biotechnology ETF (FBT): ETF Research Reports This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
13-06-2025
- Business
- Yahoo
US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Medication
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the 13 Biotech Stocks with Huge Upside Potential. It declared that the U.S. Court of Appeals maintained the legality of its composition of matter patent for the medication Nuplazid, which treats psychosis in Parkinson's disease. A research scientist looking through a microscope in a lab, symbolizing the biopharmaceutical company's innovative approach to medical treatments. The verdict supports ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in its legal struggle with India-based MSN Laboratories and upholds a December 2023 ruling by the U.S. District Court of Delaware. A later patent claim with the same priority date cannot be declared invalid by the court. According to CEO Catherine Owen Adams, Nuplazid's patent protection has been extended to 2030. The 34 mg capsule is also protected by a separate formulation patent that runs through 2038. The U.S. FDA authorized Nuplazid in 2016 to treat delusions and hallucinations linked to psychosis in Parkinson's disease. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)'s legal stance in a different action against Aurobindo Pharma was further strengthened by the latest decision. When taken as a whole, these results solidify the company's portfolio of intellectual property in the face of generic competition, guaranteeing prolonged market exclusivity for its flagship neurological medication. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical firm that specializes in the creation and marketing of medications that treat uncommon diseases and disorders of the central nervous system. While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-06-2025
- Business
- Yahoo
US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Medication
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the 13 Biotech Stocks with Huge Upside Potential. It declared that the U.S. Court of Appeals maintained the legality of its composition of matter patent for the medication Nuplazid, which treats psychosis in Parkinson's disease. A research scientist looking through a microscope in a lab, symbolizing the biopharmaceutical company's innovative approach to medical treatments. The verdict supports ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in its legal struggle with India-based MSN Laboratories and upholds a December 2023 ruling by the U.S. District Court of Delaware. A later patent claim with the same priority date cannot be declared invalid by the court. According to CEO Catherine Owen Adams, Nuplazid's patent protection has been extended to 2030. The 34 mg capsule is also protected by a separate formulation patent that runs through 2038. The U.S. FDA authorized Nuplazid in 2016 to treat delusions and hallucinations linked to psychosis in Parkinson's disease. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)'s legal stance in a different action against Aurobindo Pharma was further strengthened by the latest decision. When taken as a whole, these results solidify the company's portfolio of intellectual property in the face of generic competition, guaranteeing prolonged market exclusivity for its flagship neurological medication. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical firm that specializes in the creation and marketing of medications that treat uncommon diseases and disorders of the central nervous system. While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
05-06-2025
- Business
- Business Insider
ACADIA Pharmaceuticals (ACAD) Gets a Hold from Bank of America Securities
In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $23.00. The company's shares closed yesterday at $21.77. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Ahmad is an analyst with an average return of -1.3% and a 49.49% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Incyte, Sarepta Therapeutics, and PTC Therapeutics. In addition to Bank of America Securities, ACADIA Pharmaceuticals also received a Hold from Morgan Stanley's Sean Laaman in a report issued on May 20. However, on the same day, Deutsche Bank upgraded ACADIA Pharmaceuticals (NASDAQ: ACAD) to a Buy. ACAD market cap is currently $3.59B and has a P/E ratio of 16.00. Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACAD in relation to earlier this year. Most recently, in March 2025, ELIZABETH A. GAROFALO, a Director at ACAD sold 4,919.00 shares for a total of $89,673.37.
